Please Wait

Applying Filters...

Technical details about Oritavancin Diphosphate, learn more about the structure, uses, toxicity, action, side effects and more

Oritavancin Diphosphate

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

1 NDC API

1 NDC API

PRICE INFORMATION

API Reference Price, API Imports

DOSSIERs // Finished Dosage Forms

3 Dossiers, 2 FDA Orange Book, 1 Europe

RELATED EXCIPIENT COMPANIES

Suppliers, 12 SPI Pharma, 3 Roquette, 2 Microlex e.U, 2 Gangwal Healthcare, 2 Gangwal Chemicals, 2 Kerry, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Ingredion Pharma Solutions, 1 Pfanstiehl, 1 BASF, 1 Rochem International Inc, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

18 Fillers, Diluents & Binders, 10 Direct Compression, 10 Chewable & Orodispersible Aids, 9 Taste Masking, 4 Co-Processed Excipients, 4 Parenteral, 3 Granulation, 3 Disintegrants & Superdisintegrants, 1 API Stability Enhancers, 1 Thickeners and Stabilizers

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

1 US Medicaid Prescriptions

MARKET PLACE

4 APIs

4 APIs

PATENTS

6 US Patents, 5 US Exclusivities

DIGITAL CONTENT

3 Data Compilation & Company Tracker #PharmaFlow, 1 News

1. Also known as: Orbactiv, 192564-14-0, Ly333328 diphosphate, Oritavancin phosphate, Oritavancin (diphosphate), Ly 333328 diphosphate

Molecular Formula

C₈₆H₁₀₃Cl₃N₁₀O₃₄P₂

Molecular Weight

1989.1 g/mol

InChI Key

PWTROOMOPLCZHB-BHYQHFGMSA-N

FDA UNII

VL1P93MKZN

1 2D Structure

2D Structure

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid;phosphoric acid

2.1.2 InChI

InChI=1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1

2.1.3 InChI Key

PWTROOMOPLCZHB-BHYQHFGMSA-N

2.1.4 Canonical SMILES

CC1C(C(CC(O1)OC2C3C(=O)NC(C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)C(C(=O)N3)NC(=O)C6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)OC9C(C(C(C(O9)CO)O)O)OC1CC(C(C(O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)C(C(C(=O)NC(C(=O)N6)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O.OP(=O)(O)O.OP(=O)(O)O

2.1.5 Isomeric SMILES

C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O.OP(=O)(O)O.OP(=O)(O)O

2.2 Other Identifiers

2.2.1 UNII

VL1P93MKZN

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabinohexopyranosyl)-n3''-(p-(p-chlorophenyl)benzyl)vancomycin

2. Ly 333328

3. Ly-333328

4. Ly333328

5. Orbactiv

6. Oritavancin

2.3.2 Depositor-Supplied Synonyms

1. Orbactiv

2. 192564-14-0

3. Ly333328 Diphosphate

4. Oritavancin Phosphate

5. Oritavancin (diphosphate)

6. Ly 333328 Diphosphate

7. Oritavancin Diphosphate [usan]

8. Vl1p93mkzn

9. Ly-333328 Diphosphate

10. Kimyrsa

11. Nuvocid

12. Oritavancin Diphosphate (usan)

13. Unii-vl1p93mkzn

14. Orbactiv (tn)

15. Oritavancin Bisphosphate

16. Chembl3989766

17. Chebi:83305

18. Hy-b1831a

19. Dtxsid901027688

20. Oritavancin Diphosphate [mi]

21. Oritavancin Phosphate [mart.]

22. Cs-5054

23. Oritavancin Diphosphate [vandf]

24. Oritavancin Diphosphate [who-dd]

25. Ac-32605

26. Oritavancin Diphosphately333328, Orbactiv

27. Ly 333328 Pound>>oritavancin (phosphate)

28. Oritavancin Diphosphate [orange Book]

29. D05271

30. Q27156742

31. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin Phosphate(1:2)

32. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin Phosphate(1:2) (salt)

33. (4'r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3)'-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin Phosphate (1:2) (salt)

34. (4'r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3)'-(p-(p-chlorophenyl)benzyl)vancomycin Phosphate (1:2) (salt)

35. (4r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabinohexopyranosyl)-n3-(p-(p-chlorophenyl)benzyl)vancomycin Diphosphate

36. Vancomycin, 22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n3''-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)-, (4''r)-, Phosphate (1:2)

37. Vancomycin, 22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n3''-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)-, (4''r)-, Phosphate (1:2) (salt)

2.4 Create Date

2011-08-02

3 Chemical and Physical Properties

Molecular Formula	C₈₆H₁₀₃Cl₃N₁₀O₃₄P₂
Molecular Weight	1989.1 g/mol
Hydrogen Bond Donor Count	26
Hydrogen Bond Acceptor Count	37
Rotatable Bond Count	19
Exact Mass	1986.517897 g/mol
Monoisotopic Mass	1986.517897 g/mol
Topological Polar Surface Area	717 Å²
Heavy Atom Count	135
Formal Charge	0
Complexity	3750
Isotope Atom Count	0
Defined Atom Stereocenter Count	22
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	3

4 Drug and Medication Information

4.1 Drug Indication

Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4. 4 and 5. 1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Treatment of acute bacterial skin and skin structure infections

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

5.2 FDA Pharmacological Classification

5.2.1 Pharmacological Classes

Cytochrome P450 2C9 Inhibitors [MoA]; Cytochrome P450 2D6 Inducers [MoA]; Cytochrome P450 3A4 Inducers [MoA]; Lipoglycopeptide Antibacterial [EPC]; Lipoglycopeptides [EXT]; Cytochrome P450 2C19 Inhibitors [MoA]

5.3 ATC Code

J01XA05

POST ENQUIRY